BioCryst Pharmaceuticals

American pharmaceutical company

BCRX Nasdaq ISIN US09058V1035 SEC CIK 882796 LEI 549300Z0INP1Z5NP6J59
Follow BioCryst Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $180.3M +13.1% vs same quarter last year
Net income $37.9M +193.9% vs same quarter last year
EPS, diluted $0.14 +133.3% vs same quarter last year
Operating cash flow $33M −20.8% vs same quarter last year
Revenue by quarter
$131.5M
$145.5M
$163.4M
$159.4M
$406.6M
$156.4M
$218.3M
$180.3M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$500M$0$500M$1BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$874.8M$263.9M
FY24$450.7M−$88.9M
FY23$331.4M−$226.5M
FY22$270.8M−$247.1M
FY21$157.2M−$184.1M
FY20$17.8M−$182.8M
FY19$48.8M−$108.9M
FY18$20.7M−$101.3M
FY17$25.2M−$65.8M
FY16$26.4M−$55.1M
FY15$48.3M−$43M
FY14$13.6M−$45.2M
FY13$17.3M−$30.1M
FY12$26.3M−$39.1M
FY11$19.6M−$56.9M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−1500%−1000%−500%0%500%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2597.8%39%30.2%
FY2497.3%−0.6%−19.7%
FY2398.6%−31.3%−68.4%
FY2297.6%−54.8%−91.2%
FY2195.4%−113.1%−117.1%
FY2091.3%−981.1%−1026.4%
FY1992.4%−203.7%−223%
FY18-−456.2%−490.3%
FY1795.5%−227.9%−261.2%
FY1691.3%−184.4%−209.3%
FY1597.2%−81.7%−89.1%
FY14100%−336.4%−332.1%
FY13-−177.2%−173.7%
FY12-−128.9%−148.6%
FY11-−252.4%−289.9%
Free cash flowOperating cash flow minus capital expenditure
−$200M$0$200M$400MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25$344.9M
FY24−$53.1M
FY23−$97.3M
FY22−$163.2M
FY21−$144.5M
FY20−$135.6M
FY19−$89.9M
FY18−$92.9M
FY17−$41.5M
FY16−$58.7M
FY15−$18.2M
FY14−$38.7M
FY13−$26.6M
FY12−$37.5M
FY11−$32.3M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • BioCryst Pharmaceuticals
  • Healthcare median
−1500%−1000%−500%0%500%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBioCryst PharmaceuticalsHealthcare median
FY2530.2%−30.6%
FY24−19.7%−47%
FY23−68.4%−58%
FY22−91.2%−80.4%
FY21−117.1%−71.8%
FY20−1026.4%−62.2%
FY19−223%−46.2%
FY18−490.3%−49.6%
FY17−261.2%−45.9%
FY16−209.3%−36%
FY15−89.1%−37.8%
FY14−332.1%−35.5%
FY13−173.7%−37.1%
FY12−148.6%−29.1%
FY11−289.9%−27.9%